Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 EBITDA Margin % is 35.87% as of Dec. 2025, which is 4% below its 10-year median of 37.28. GuruFocus rates CPHGF with a GF Score™ of 55/100 and a GF Value™ of $0.60 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 959 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 90.93% on this metric.
Consun Pharmaceutical Group (OTCPK:CPHGF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Consun Pharmaceutical Group EBITDA Margin % Related Terms
Consun Pharmaceutical Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a EBITDA Margin % of 35.87% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Consun Pharmaceutical Group and its competitors. This is near median its historical median of 37.28. Over the past decade, Consun Pharmaceutical Group's EBITDA Margin % has ranged from 13.65 to 38.81. According to the industry distribution chart, Consun Pharmaceutical Group ranks #87 out of 959 companies in the Drug Manufacturers industry, placing it in the top 9.1%.
Is Consun Pharmaceutical Group's EBITDA Margin % too high?
Consun Pharmaceutical Group's current EBITDA Margin % of 35.87% is near median its 10-year median of 37.28. Over the past 10 years, this metric has ranged from a low of 13.65 to a high of 38.81. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Consun Pharmaceutical Group's value of 35.87% is 186% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #87 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #87 out of 959 companies for EBITDA Margin %. This places Consun Pharmaceutical Group in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Consun Pharmaceutical Group's value of 35.87% is 186% above this benchmark. Historically, Consun Pharmaceutical Group's own EBITDA Margin % has ranged from 13.65 to 38.81 over the past decade. While the company's 10-year median is 37.28 vs. the industry median of 12.54, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current EBITDA Margin % of 35.87% is 186% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current EBITDA Margin % is 35.87%, which is near median its own 10-year median of 37.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.60, compared to a current price of $1.80 — trading 200% above its estimated fair value. The current EBITDA Margin % is 35.87%, which is near median its 10-year median of 37.28 and 186% above the Drug Manufacturers industry median of 12.54. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current EBITDA Margin % is 35.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 200% above its estimated GF Value™ of $0.60.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
EBITDA Margin %: 35.87% (near median its 10-year median of 37.28)
GF Value™: $0.60 vs. price of $1.80 (200% above fair value)
Industry Position: 186% above the Drug Manufacturers median (#87 of 959)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
